These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26082235)

  • 1. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
    Giddens JP; Wang LX
    Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
    Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
    J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins.
    Yang Q; Wang LX
    Methods Enzymol; 2017; 597():265-281. PubMed ID: 28935106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-pot enzymatic glycan remodeling of a therapeutic monoclonal antibody by endoglycosidase S (Endo-S) from Streptococcus pyogenes.
    Tong X; Li T; Orwenyo J; Toonstra C; Wang LX
    Bioorg Med Chem; 2018 Apr; 26(7):1347-1355. PubMed ID: 28789910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation.
    Yang Q; An Y; Zhu S; Zhang R; Loke CM; Cipollo JF; Wang LX
    ACS Chem Biol; 2017 Jun; 12(6):1665-1673. PubMed ID: 28452462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.
    Zou G; Ochiai H; Huang W; Yang Q; Li C; Wang LX
    J Am Chem Soc; 2011 Nov; 133(46):18975-91. PubMed ID: 22004528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoenzymatic Defucosylation of Therapeutic Antibodies for Enhanced Effector Functions Using Bacterial α-Fucosidases.
    Li C; Li T; Wang LX
    Methods Mol Biol; 2018; 1827():367-380. PubMed ID: 30196507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific immobilization of endoglycosidases for streamlined chemoenzymatic glycan remodeling of antibodies.
    Li T; Li C; Quan DN; Bentley WE; Wang LX
    Carbohydr Res; 2018 Mar; 458-459():77-84. PubMed ID: 29475193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endo-F3 Glycosynthase Mutants Enable Chemoenzymatic Synthesis of Core-fucosylated Triantennary Complex Type Glycopeptides and Glycoproteins.
    Giddens JP; Lomino JV; Amin MN; Wang LX
    J Biol Chem; 2016 Apr; 291(17):9356-70. PubMed ID: 26966183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation.
    Wei Y; Li C; Huang W; Li B; Strome S; Wang LX
    Biochemistry; 2008 Sep; 47(39):10294-304. PubMed ID: 18771295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.
    Li T; Tong X; Yang Q; Giddens JP; Wang LX
    J Biol Chem; 2016 Aug; 291(32):16508-18. PubMed ID: 27288408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans.
    Sjögren J; Cosgrave EF; Allhorn M; Nordgren M; Björk S; Olsson F; Fredriksson S; Collin M
    Glycobiology; 2015 Oct; 25(10):1053-63. PubMed ID: 26156869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A common glycan structure on immunoglobulin G for enhancement of effector functions.
    Lin CW; Tsai MH; Li ST; Tsai TI; Chu KC; Liu YC; Lai MY; Wu CY; Tseng YC; Shivatare SS; Wang CH; Chao P; Wang SY; Shih HW; Zeng YF; You TH; Liao JY; Tu YC; Lin YS; Chuang HY; Chen CL; Tsai CS; Huang CC; Lin NH; Ma C; Wu CY; Wong CH
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10611-6. PubMed ID: 26253764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
    Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a Mutant Mucor hiemalis Endoglycosidase That Acts on Core-fucosylated N-Glycans.
    Katoh T; Katayama T; Tomabechi Y; Nishikawa Y; Kumada J; Matsuzaki Y; Yamamoto K
    J Biol Chem; 2016 Oct; 291(44):23305-23317. PubMed ID: 27629418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.
    Bennett LD; Yang Q; Berquist BR; Giddens JP; Ren Z; Kommineni V; Murray RP; White EL; Holtz BR; Wang LX; Marcel S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.